Pain in cervical dystonia: mechanisms, assessment and treatment

References

• Grütz K, Klein C. Dystonia updates: definition, nomenclature, clinical classification, and etiology. J Neural Transm. 2021;128(4):395–404.
   PubMed Web of Science ®Google Scholar
• Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol. 2011;18(1):5–18.
   PubMed Web of Science ®Google Scholar
• LaHue SC, Albers K, Goldman S, et al. Cervical dystonia incidence and diagnostic delay in a multiethnic population. Mov Disord. 2020;35(3):450–456.
   PubMed Web of Science ®Google Scholar
• Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(7):435–450.
   PubMed Web of Science ®Google Scholar
• Stamelou M, Edwards MJ, Hallett M, et al. The non-motor syndrome of primary dystonia: clinical and pathophysiological implications. Brain. 2011;135(6):1668–1681.
   PubMedGoogle Scholar
• Avanzino L, Cherif A, Crisafulli O, et al. Tactile and proprioceptive dysfunction differentiates cervical dystonia with and without tremor. Neurology. 2020;94(6):e639–e50.
   PubMed Web of Science ®Google Scholar
• Torres J, Rosales RL. Nonmotor symptoms in dystonia. Int Rev Neurobiol. 2017;134:1335–1371.
   PubMed Web of Science ®Google Scholar
• Smit M, Kuiper A, Han V, et al. Psychiatric co-morbidity is highly prevalent in idiopathic cervical dystonia and significantly influences health-related quality of life: results of a controlled study. Parkinsonism Relat Disord. 2016;30:7–12.
   PubMed Web of Science ®Google Scholar
• van den Dool J, Tijssen MA, Koelman JH, et al. Determinants of disability in cervical dystonia. Parkinsonism Relat Disord. 2016;32:48–53.
   PubMed Web of Science ®Google Scholar
• Charles PD, Adler CH, Stacy M, et al. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy). J Neurol. 2014;261(7):1309–1319.
   PubMed Web of Science ®Google Scholar
• Muller J, Kemmler G, Wissel J, et al. The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol. 2002;249(7):842–846.
   PubMed Web of Science ®Google Scholar
• Novak I, Campbell L, Boyce M, et al. Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: international consensus statement. Eur J Neurol. 2010;17(Suppl 2):94–108.
   PubMedGoogle Scholar
• Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord. 1991;6(2):119–126.
   PubMed Web of Science ®Google Scholar
• Comella C, Ferreira JJ, Pain E, et al. Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia. J Neurol. 2021;268(3):903–912.
   PubMed Web of Science ®Google Scholar
• Comella C, Bhatia K. An international survey of patients with cervical dystonia. J Neurol. 2015;262(4)837-848.
   PubMed Web of Science ®Google Scholar
• Simpson DM, Hallett M, Ashman EJ. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Neurology. 2016;86:1–9.
   Web of Science ®Google Scholar
• Williams L, McGovern E, Kimmich O, et al. Epidemiological, clinical and genetic aspects of adult onset isolated focal dystonia in Ireland. Eur J Neurol. 2017;24(1):73–81.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Leder S, Warner D, et al. Cervical dystonia: clinical findings and associated movement disorders. Neurology. 1991;41(7):1088–1091.
   PubMed Web of Science ®Google Scholar
• Kutvonen O, Dastidar P, Nurmikko T. Pain in spasmodic torticollis. Pain. 1997;69(3):279–286.
   PubMed Web of Science ®Google Scholar
• Barbanti P, Fabbrini G, Pauletti C, et al. Headache in cranial and cervical dystonia. Neurology. 2005;64(7):1308–1309.
   PubMed Web of Science ®Google Scholar
• Sheehy MP, Marsden CD. Trauma and pain in spasmodic torticollis. Lancet. 1980;1(8171):777–778.
   PubMed Web of Science ®Google Scholar
• Heinen F, Scheidt CE, Nickel T, et al. Spasmodic torticollis - a multicentre study on behavioural aspects II: signs, symptoms and course. Behav Neurol. 1996;9(2):81–88.
   PubMed Web of Science ®Google Scholar
• Marciniec M, Szczepańska-Szerej A, Popek-Marciniec S, et al. Pain incidence in cervical dystonia is determined by the disease phenotype. J Clin Neurosci. 2020;79:133–136.
   PubMed Web of Science ®Google Scholar
• Antonini A, Tinazzi M, Abbruzzese G, et al. Pain in Parkinson’s disease: facts and uncertainties. Eur J Neurol. 2018;25(7):917–e69.
   PubMed Web of Science ®Google Scholar
• Marciniec M, Szczepańska-Szerej A, Kulczyński M, et al. Pain in cervical dystonia and the antinociceptive effects of botulinum toxin: what is currently known? Rev Neurosci. 2019;30(7):771-779.
   PubMed Web of Science ®Google Scholar
• Lorentz IT, Subramaniam SS, Yiannikas C. Treatment of idiopathic spasmodic torticollis with botulinum toxin A: a double-blind study on twenty-three patients. Mov Disord. 1991;6(2):145–150.
   PubMed Web of Science ®Google Scholar
• Pappert EJ, Germanson T. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord. 2008;23(4):510–517.
   PubMed Web of Science ®Google Scholar
• Quagliato EM, Carelli EF, Viana MA. A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia. Clin Neuropharmacol. 2010;33(1):22–26.
   PubMed Web of Science ®Google Scholar
• Camargo CH, Teive HA, Becker N, et al. Botulinum toxin type A and cervical dystonia: a seven-year follow-up. Arq Neuropsiquiatr. 2011;69(5):745–750.
   PubMed Web of Science ®Google Scholar
• Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord. 1987;2(4):237–254.
   PubMed Web of Science ®Google Scholar
• Kulisevsky J, Lleó A, Gironell A, et al. Bilateral pallidal stimulation for cervical dystonia: dissociated pain and motor improvement. Neurology. 2000;55(11):1754–1755.
   PubMed Web of Science ®Google Scholar
• Cacciola F, Farah JO, Eldridge PR, et al. Bilateral deep brain stimulation for cervical dystonia: long-term outcome in a series of 10 patients. Neurosurgery. 2010;67(4):957–963.
   PubMed Web of Science ®Google Scholar
• Castagna A, Albanese A. Management of cervical dystonia with botulinum neurotoxins and EMG/ultrasound guidance. Neurol Clin Pract. 2019;9(1):64–73.
   PubMedGoogle Scholar
• Trosch R, Misra P, Maisonobe P, et al. Geographic differences in pain perception in patients with cervical Dystonia (P1.033). Neurology. 2016;86:1–33.
   Web of Science ®Google Scholar
• Consky E, Lang AE. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M, editors. Therapy with bofulinum toxin. New York: Marcel Dekker; 1994:211-237.
   Google Scholar
• Comella CL, Perlmutter JS, Jinnah HA, et al. Clinimetric testing of the comprehensive cervical dystonia rating scale. Mov Disord. 2016;31(4):563–569.
   PubMed Web of Science ®Google Scholar
• Cano SJ, Warner TT, Linacre JM, et al. Capturing the true burden of dystonia on patients: the cervical dystonia impact profile (CDIP-58). Neurology. 2004;63(9):1629–1633.
   PubMed Web of Science ®Google Scholar
• Cano SJ, Hobart JC, Edwards M, et al. CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia. Neurology. 2006;67(12):2230–2232.
   PubMed Web of Science ®Google Scholar
• Müller J, Wissel J, Kemmler G, et al. Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. J Neurol Neurosurg. 2004;75(5):749–753.
   PubMed Web of Science ®Google Scholar
• EuroQol G. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. PAIN. 2005;113(1):9–19.
   PubMed Web of Science ®Google Scholar
• Mense S. Muscle pain: mechanisms and clinical significance. Dtsch Arztebl Int. 2008;105(12):214–219.
   PubMed Web of Science ®Google Scholar
• Lund JP, Donga R, Widmer CG, et al. The pain-adaptation model: a discussion of the relationship between chronic musculoskeletal pain and motor activity. Can J Physiol Pharmacol. 1991;69(5):683–694.
   PubMed Web of Science ®Google Scholar
• Camargo CH, Cattai L, Teive HA. Pain relief in cervical Dystonia with botulinum toxin treatment. Toxins (Basel). 2015;7(6):2321–2335.
   PubMed Web of Science ®Google Scholar
• Avenali M, De Icco R, Tinazzi M, et al. Pain in focal dystonias - A focused review to address an important component of the disease. Parkinsonism Relat Disord. 2018;54:17–24.
   PubMed Web of Science ®Google Scholar
• Lobbezoo F, Tanguay R, Thon MT, et al. Pain perception in idiopathic cervical dystonia (spasmodic torticollis). Pain. 1996;67(2–3):483–491.
   PubMed Web of Science ®Google Scholar
• Paracka L, Wegner F, Blahak C, et al. Sensory alterations in patients with isolated idiopathic Dystonia: an exploratory quantitative sensory testing analysis. Front Neurol. 2017;8:553.
   PubMed Web of Science ®Google Scholar
• Tinazzi M, Valeriani M, Squintani G, et al. Nociceptive pathway function is normal in cervical dystonia: a study using laser-evoked potentials. J Neurol. 2012;259(10):2060–2066.
   PubMed Web of Science ®Google Scholar
• Tinazzi M, Squintani GM, Bhatia KP, et al. Pain in cervical dystonia: evidence of abnormal inhibitory control. Parkinsonism Relat Disord. 2019;65:252–255.
   PubMed Web of Science ®Google Scholar
• Ossipov MH, Morimura K, Porreca F. Descending pain modulation and chronification of pain. Curr Opin Support Palliat Care. 2014;8(2):143–151.
   PubMed Web of Science ®Google Scholar
• Hallett M. Pathophysiology of dystonia. J Neural Transm Suppl. 2006;70(Suppl):485–488.
   PubMedGoogle Scholar
• Poisson A, Krack P, Thobois S, et al. History of the ‘geste antagoniste’ sign in cervical dystonia. J Neurol. 2012;259(8):1580–1584.
   PubMed Web of Science ®Google Scholar
• Patel N, Jankovic J, Hallett M. Sensory aspects of movement disorders. Lancet Neurol. 2014;13(1):100–112.
   PubMed Web of Science ®Google Scholar
• Shakkottai VG, Batla A, Bhatia K, et al. Current opinions and areas of consensus on the role of the cerebellum in Dystonia. Cerebellum. 2017;16(2):577–594.
   PubMed Web of Science ®Google Scholar
• Brüggemann N. Contemporary functional neuroanatomy and pathophysiology of dystonia. J Neural Transm (Vienna). 2021;128(4):499–508.
   PubMed Web of Science ®Google Scholar
• Prell T, Peschel T, Köhler B, et al. Structural brain abnormalities in cervical dystonia. BMC Neurosci. 2013;14:123.
   PubMed Web of Science ®Google Scholar
• Brodoehl S, Wagner F, Prell T, et al. Cause or effect: altered brain and network activity in cervical dystonia is partially normalized by botulinum toxin treatment. Neuroimage Clin. 2019;22:101792.
   PubMed Web of Science ®Google Scholar
• Quartarone A, Hallett M. Emerging concepts in the physiological basis of dystonia. Mov Disord. 2013;28(7):958–967.
   PubMed Web of Science ®Google Scholar
• Denk F, McMahon SB, Tracey I. Pain vulnerability: a neurobiological perspective. Nat Neurosci. 2014;17(2):192–200.
   PubMed Web of Science ®Google Scholar
• Konrad C, Vollmer-Haase J, Anneken K, et al. Orthopedic and neurological complications of cervical dystonia–review of the literature. Acta Neurol Scand. 2004;109(6):369–373.
   PubMed Web of Science ®Google Scholar
• Duane DD. Spasmodic torticollis: clinical and biologic features and their implications for focal dystonia. Adv Neurol. 1988;50:473–492.
   PubMedGoogle Scholar
• Trosch RM, Espay AJ, Truong D, et al. Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: the ANCHOR-CD registry. J Neurol Sci. 2017;376:84–90.
   PubMed Web of Science ®Google Scholar
• Mahajan A, Jankovic J, Marsh L, et al. Cervical dystonia and substance abuse. J Neurol. 2018;265(4):970–975.
   PubMed Web of Science ®Google Scholar
• Brans JW, Lindeboom R, Snoek JW, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology. 1996;46(4):1066–1072.
   PubMed Web of Science ®Google Scholar
• Costa J, Espirito-Santo C, Borges A, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev. 2005;1:CD003633.
   PubMed Web of Science ®Google Scholar
• Rodrigues FB, Duarte GS, Marques RE, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev. 2020;11(11):CD003633.
   Web of Science ®Google Scholar
• Esquenazi A, Delgado MR, Hauser RA, et al. Duration of symptom relief between injections for abobotulinumtoxinA (Dysport(R)) in spastic paresis and cervical dystonia: comparison of evidence from clinical studies. Front Neurol. 2020;11:576117.
   PubMed Web of Science ®Google Scholar
• Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005;20(7):783–791.
   PubMed Web of Science ®Google Scholar
• Truong D, Brodsky M, Lew M, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010;16(5):316–323.
   PubMed Web of Science ®Google Scholar
• Poewe W, Burbaud P, Castelnovo G, et al. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: a randomized-controlled trial. Mov Disord. 2016;31(11):1649–1657.
   PubMed Web of Science ®Google Scholar
• Lew MF, Brashear A, Dashtipour K, et al. A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia. Int J Neurosci. 2018;128(7):619–626.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Truong D, Hubble J, et al. AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies. J Neural Transm (Vienna). 2013;120(2):299–307.
   PubMed Web of Science ®Google Scholar
• Dashtipour K, Wietek S, Rubin B, et al. AbobotulinumtoxinA using 2-mL dilution (500 U/2-mL) maintains durable improvement across multiple treatment cycles. J Clin Mov Disord. 2020;7:8.
   PubMedGoogle Scholar
• Trosch RM, Misra VP, Maisonobe P, et al. Impact of abobotulinumtoxinA on the clinical features of cervical dystonia in routine practice. Clin Parkinsonism Relat Disord. 2020;3:100063.
   PubMedGoogle Scholar
• Marciniec M, Szczepańska-Szerej A, Rejdak K. Cervical dystonia: factors deteriorating patient satisfaction of long-term treatment with botulinum toxin. Neurol Res. 2020;42(11):987–991.
   PubMed Web of Science ®Google Scholar
• Poewe W, Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry. 1998;64(1):13–17.
   PubMed Web of Science ®Google Scholar
• Yun JY, Kim JW, Kim HT, et al. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study. Mov Disord. 2015;30(2):206–213.
   PubMed Web of Science ®Google Scholar
• Dressler D, Bigalke H. Pharmacology of botulinum toxin drugs. In: Truong DMD, Dressler D, Hallett M, et al., editors. Manual of botulinum toxin therapy. Cambridge: Cambridge University Press; 2009;13-23.
   Google Scholar
• Filippi GM, Errico P, Santarelli R, et al. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol. 1993;113(3):400–404.
   PubMed Web of Science ®Google Scholar
• Trompetto C, Currà A, Buccolieri A, et al. Botulinum toxin changes intrafusal feedback in dystonia: a study with the tonic vibration reflex. Mov Disord. 2006;21(6):777–782.
   PubMed Web of Science ®Google Scholar
• Marciniec M, Szczepańska-Szerej A, Kulczyński M, et al. Pain in cervical dystonia and the antinociceptive effects of botulinum toxin: what is currently known? Rev Neurosci. 2019;30(7):771–779.
   PubMed Web of Science ®Google Scholar
• Siongco PRL, Rosales RL, Moore AP, et al. Botulinum neurotoxin injections for muscle-based (dystonia and spasticity) and non-muscle-based (neuropathic pain) pain disorders: a meta-analytic study. J Neural Transm (Vienna). 2020;127(6):935–951.
   PubMed Web of Science ®Google Scholar
• Park J, Park HJ. Botulinum toxin for the treatment of neuropathic pain. Toxins (Basel). 2017;9:9.
   Web of Science ®Google Scholar
• Matak I, Lacković Z. Botulinum toxin A, brain and pain. Prog Neurobiol. 2014;119-120:39–59.
   PubMed Web of Science ®Google Scholar
• Wheeler A, Smith HS. Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology. 2013;306:124–146.
   PubMed Web of Science ®Google Scholar
• Kim D-W, Lee S-K, Ahnn J. Botulinum toxin as a pain killer: players and actions in antinociception. Toxins (Basel). 2015;7(7):2435–2453.
   PubMed Web of Science ®Google Scholar
• Delnooz CC, Pasman JW, Beckmann CF. Task-free functional MRI in cervical dystonia reveals multi-network changes that partially normalize with botulinum toxin. PLoS One. 2013;8(5):e62877.
   PubMed Web of Science ®Google Scholar
• Rosales RL, Dressler D. On muscle spindles, dystonia and botulinum toxin. Eur J Neurol. 2010;17(Suppl 1):71–80.
   PubMed Web of Science ®Google Scholar
• Feng L, Zhang Z, Malam Djibo I, et al. The efficacy of single-photon emission computed tomography in identifying dystonic muscles in cervical dystonia. Nucl Med Commun. 2020;41(7):651–658.
   PubMed Web of Science ®Google Scholar
• Bergenheim AT, Nordh E, Larsson E, et al. Selective peripheral denervation for cervical dystonia: long-term follow-up. J Neurol Neurosurg. 2015;86(12):1307–1313.
   Web of Science ®Google Scholar
• Cohen-Gadol AA, Ahlskog JE, Matsumoto JY, et al. Selective peripheral denervation for the treatment of intractable spasmodic torticollis: experience with 168 patients at the Mayo Clinic. J Neurosurg. 2003;98(6):1247–1254.
   PubMed Web of Science ®Google Scholar
• Münchau A, Palmer JD, Dressler D, et al. Prospective study of selective peripheral denervation for botulinum-toxin resistant patients with cervical dystonia. Brain. 2001;124(Pt 4):769–783.
   PubMedGoogle Scholar
• Loher TJ, Capelle HH, Kaelin-Lang A, et al. Deep brain stimulation for dystonia: outcome at long-term follow-up. J Neurol. 2008;255(6):881–884.
   PubMed Web of Science ®Google Scholar
• Skogseid IM, Ramm-Pettersen J, Volkmann J, et al. Good long-term efficacy of pallidal stimulation in cervical dystonia: a prospective, observer-blinded study. Eur J Neurol. 2012;19(4):610–615.
   PubMed Web of Science ®Google Scholar
• Ostrem JL, Racine CA, Glass GA, et al. Subthalamic nucleus deep brain stimulation in primary cervical dystonia. Neurology. 2011;76(10):870–878.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Jeon B. Arching deep brain stimulation in dystonia types. J Neural Transm (Vienna). 2021;128(4):539–547.
   PubMed Web of Science ®Google Scholar
• Bradnam LV, Meiring RM, Boyce M, et al. Neurorehabilitation in dystonia: a holistic perspective. J Neural Transm. 2021;128(4):549–558.
   PubMed Web of Science ®Google Scholar
• De Pauw J, Van der Velden K, Meirte J, et al. The effectiveness of physiotherapy for cervical dystonia: a systematic literature review. J Neurol. 2014;261(10):1857–1865.
   PubMed Web of Science ®Google Scholar
• Franco JH, Rosales RL. Neurorehabilitation in dystonia (Chapter 14). In: Kanovsky P, Bhatia K, Rosales RL, editors. Dystonia and dystonic syndromes. Germany: Springer, GmbH; 2015. ISBN 978-3-7091-1515-2 ISBN 978-3-7091-1516-9 (eBook). DOI: https://doi.org/10.1007/978-3-7091-1516-9)
   Google Scholar
• Delnooz CC, Horstink MW, Tijssen MA. Paramedical treatment in primary dystonia: a systematic review. Mov Disord. 2009;24(15):2187–2198.
   PubMed Web of Science ®Google Scholar
• Queiroz MA, Chien HF, Sekeff-Sallem FA, et al. Physical therapy program for cervical dystonia: a study of 20 cases. Funct Neurol. 2012;27(3):187–192.
   PubMed Web of Science ®Google Scholar
• Tassorelli C, Mancini F, Balloni L, et al. Botulinum toxin and neuromotor rehabilitation: an integrated approach to idiopathic cervical dystonia. Mov Disord. 2006;21(12):2240–2243.
   PubMed Web of Science ®Google Scholar
• Hu W, Rundle-Gonzalez V, Kulkarni SJ, et al. A randomized study of botulinum toxin versus botulinum toxin plus physical therapy for treatment of cervical dystonia. Parkinsonism Relat Disord. 2019;63:195–198.
   PubMed Web of Science ®Google Scholar
• Kaňovský P, Rosales R, Otruba P, et al. Contemporary clinical neurophysiology applications in dystonia. J Neural Transm (Vienna). 2021;128(4):509–519.
   PubMed Web of Science ®Google Scholar
• Angelakis E, Liouta E, Andreadis N, et al. Transcranial alternating current stimulation reduces symptoms in intractable idiopathic cervical dystonia: a case study. Neurosci Lett. 2013;533:39–43.
   PubMed Web of Science ®Google Scholar
• Bradnam LV, Frasca J, Kimberley TJ. Direct current stimulation of primary motor cortex and cerebellum and botulinum toxin a injections in a person with cervical dystonia. Brain Stimul. 2014;7(6):909–911.
   PubMed Web of Science ®Google Scholar
• Lizarraga KJ, Al-Shorafat D, Fox S. Update on current and emerging therapies for dystonia. Neurodegener Dis Manag. 2019;9(3):135–147.
   PubMed Web of Science ®Google Scholar
• Fietzek UM, Nene D, Schramm A, et al. The role of ultrasound for the personalized botulinum toxin treatment of cervical dystonia. Toxins (Basel). 2021;13(5):365.
   PubMed Web of Science ®Google Scholar
• Kaymak B, Gürçay E, Ata AM, et al. Ultrasound imaging and guidance in the management of cervical dystonia: a caveat on the compartmentalization of sternocleidomastoid muscle. Parkinsonism Relat Disord. 2017;43:127–128.
   PubMed Web of Science ®Google Scholar
• Esquenazi A, Delgado MR, Hauser RA, et al. Duration of symptom relief between injections for abobotulinumtoxinA (Dysport®) in spastic paresis and cervical dystonia: comparison of evidence from clinical studies. Front Neurol. 2020;11:576117.
   PubMed Web of Science ®Google Scholar
• Colosimo C, Charles D, Misra VP, et al. group IICs. Cumulative effects of long-term treatment with abobotulinumtoxinA in cervical dystonia: findings from a prospective, observational study. J Neurol Sci. 2020;416:117015.
   PubMed Web of Science ®Google Scholar
• Jost WH Torticaput versus torticollis: clinical effects with modified classification and muscle selection. Tremor and other hyperkinetic movements (New York, NY). 2019;9:DOI: https://doi.org/10.7916/tohm.v0.647.
   Google Scholar
• Jost WH, Biering-Sørensen B, Drużdż A, et al. Preferred muscles in cervical dystonia. Neurol Neurochir Pol. 2020;54(3):277–279.
   PubMed Web of Science ®Google Scholar
• Demetrios M, Khan F, Turner-Stokes L, et al. Multidisciplinary rehabilitation following botulinum toxin and other focal intramuscular treatment for post-stroke spasticity. Cochrane Database Syst Rev. 2013;6:Cd009689.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Truong D, Patel AT, et al. Injectable daxibotulinumtoxina in cervical dystonia: a phase 2 dose-escalation multicenter study. Mov Disord Clin Pract. 2018;5(3):273–282.
   PubMed Web of Science ®Google Scholar
• A phase 2 study to evaluate the safety and efficacy of ABP-450 in the treatment of cervical dystonia. NCT04849988. Available from https://clinicaltrials.gov/ct2/show/NCT04849988. Last accessed Sept 2021.
   Google Scholar
• Kim D-Y, Kim JM. Safety and efficacy of prabotulinumtoxinA (Nabota®) injection for cervical and shoulder girdle myofascial pain syndrome: a pilot study. Toxins (Basel). 2018;10(9):355.
   Web of Science ®Google Scholar
• Chaddock JA, Marks PM. Clostridial neurotoxins: structure-function led design of new therapeutics. Cell Mol Life Sci. 2006;63(5):540–551.
   PubMed Web of Science ®Google Scholar
• Tehran DA, Pirazzini M. Novel botulinum neurotoxins: exploring underneath the iceberg tip. Toxins (Basel). 2018;10(5):190.
   Web of Science ®Google Scholar
• Foster KA. Engineered toxins: new therapeutics. Toxicon. 2009;54(5):587–592.
   PubMed Web of Science ®Google Scholar
• Rummel A, Mahrhold S, Bigalke H, et al. Exchange of the H(CC) domain mediating double receptor recognition improves the pharmacodynamic properties of botulinum neurotoxin. Febs J. 2011;278(23):4506–4515.
   PubMed Web of Science ®Google Scholar
• Wang J, Zurawski TH, Bodeker MO, et al. Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B. Biochem J. 2012;444(1):59–67.
   PubMedGoogle Scholar
• Guo J, Pan X, Zhao Y, et al. Engineering clostridia neurotoxins with elevated catalytic activity. Toxicon. 2013;74:158–166.
   PubMed Web of Science ®Google Scholar
• Wang D, Zhang Z, Dong M, et al. Syntaxin requirement for Ca2+-triggered exocytosis in neurons and endocrine cells demonstrated with an engineered neurotoxin. Biochemistry. 2011;50(14):2711–2713.
   PubMed Web of Science ®Google Scholar
• Foster K, Chaddock J. Targeted secretion inhibitors-innovative protein therapeutics. Toxins (Basel). 2010;2(12):2795–2815.
   PubMed Web of Science ®Google Scholar
• Stancombe PR, Masuyer G, Birch-Machin I, et al. Engineering botulinum neurotoxin domains for activation by toxin light chain. Febs J. 2012;279(3):515–523.
   PubMed Web of Science ®Google Scholar